The estimated Net Worth of James E Brown is at least 901 千$ dollars as of 27 November 2018. Dr Brown owns over 10,000 units of Durect Corp stock worth over 125,600$ and over the last 21 years he sold DRRX stock worth over 0$. In addition, he makes 775,884$ as Co-Founder、 CEO、 Pres & Director at Durect Corp.
Sign up
Dr M DRRX stock SEC Form 4 insiders trading
Dr has made over 4 trades of the Durect Corp stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of DRRX stock worth 8,100$ on 27 November 2018.
The largest trade he's ever made was buying 30,000 units of Durect Corp stock on 4 June 2013 worth over 24,000$. On average, Dr trades about 1,860 units every 57 days since 2003. As of 27 November 2018 he still owns at least 80,000 units of Durect Corp stock.
You can see the complete history of Dr Brown stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. James E. Brown D.V.M. biography
Dr. James E. Brown D.V.M. is the Co-Founder, CEO, Pres & Director at Durect Corp.
What is the salary of Dr M?
As the Co-Founder、 CEO、 Pres & Director of Durect Corp, the total compensation of Dr M at Durect Corp is 775,884$. There are no executives at Durect Corp getting paid more.
How old is Dr M?
Dr M is 64, he's been the Co-Founder、 CEO、 Pres & Director of Durect Corp since . There are 2 older and 2 younger executives at Durect Corp. The oldest executive at Durect Corp is Dr. Su Il Yum Ph.D., 82, who is the Exec. Officer.
What's Dr M's mailing address?
James's mailing address filed with the SEC is C/O DURECT CORPORATION, 10240 BUBB ROAD, CUPERTINO, CA, 95014.
Insiders trading at Durect Corp
Over the last 21 years, insiders at Durect Corp have traded over 528,010$ worth of Durect Corp stock and bought 19,954,650 units worth 23,296,708$ . The most active insiders traders include April Fund Ltd21 April Fund...、Eagle Investment Management...、Felix Theeuwes. On average, Durect Corp executives and independent directors trade stock every 55 days with the average trade being worth of 468,485$. The most recent stock trade was executed by Judith J. Robertson on 18 August 2022, trading 80,942 units of DRRX stock currently worth 68,801$.
What does Durect Corp do?
durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
What does Durect Corp's logo look like?
Complete history of Dr Brown stock trades at Durect Corp
Durect Corp executives and stock owners
Durect Corp executives and other stock owners filed with the SEC include:
-
Dr. James E. Brown D.V.M.,
Co-Founder, CEO, Pres & Director -
Michael H. Arenberg,
CFO & Sec. -
Dr. Norman L. Sussman,
Chief Medical Officer -
Judy R. Joice,
Sr. VP of Operations & Corp. Quality Assurance -
Dr. Su Il Yum Ph.D.,
Exec. Officer -
Jian Li M.B.A.,
VP of Fin. & Corp. Controller -
Dr. WeiQi Lin,
Exec. VP of R&D and Principal Scientist -
Steve Helmer J.D.,
VP & Chief Patent Counsel -
Dr. Andrew R. Miksztal,
VP of Pharmaceutical R&D and Principal Scientist -
Judy R Joice,
Sr. VP Operations & Corp QA -
April Fund Ltd21 April Fund...,
-
April Fund Ltd Arnhold & S....,
-
Dave Hoffmann,
Director -
Jon S Saxe,
Director -
Terrence F Blaschke,
Director -
Jay Shepard,
Director -
Armand Neukermans,
Director -
Simon X Benito,
Director -
Eagle Investment Management...,
-
April Fund Ltd21 April Fund...,
-
Matthew J Hogan,
Chief Financial Officer -
Michael Arenberg,
Chief Financial Officer -
Judith J. Robertson,
Director -
Gail M Farfel,
Director -
Paula V Mendenhall,
Sr. VP of Operations -
Su Il Yum,
Exec. VP Pharm./R&D -
Michael D Casey,
Director -
Joseph William Stauffer,
CMO and Exec.VP Corp. Strategy -
Jean I Liu,
Senior VP & General Counsel -
Edward M Gillis,
VP Engineering -
Thomas A Schreck,
Chief Financial Officer -
Michael J Taylor,
VP, Non Clinical Research -
Felix Theeuwes,
Chairman and CSO -
Arthur J Tipton,
Sr.VP Bioerodible Product Dev. -
Timothy S Nelson,
Senior VP Business & Dev. -
Peter Langecker,
Chief Medical Officer -
Tai Wah Chan,
VP Pharmaceutical Research -
Steven Halladay,
VP Clinical and Regulatory -
Li Jian,
VP Finance and Controller -
Lp Bleichroeder,
10% owner -
Eagle Investment Management...,
-
Mohammad Azab,
Director -
Gail J Maderis,
Director -
Peter S Garcia,
Director -
James E Brown,
President & CEO -
Timothy M. Papp,
Chief Financial Officer -
Norman Sussman,
Chief Medical Officer